David Planchard

David Planchard's AcademicInfluence.com Rankings

David Planchard

Philosophy

#7688

World Rank

#10935

Historical Rank

Logic

#4728

World Rank

#6053

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David Planchard's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is David Planchard Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Planchard's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018) (2753)
Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer (2017) (1959)
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. (2015) (1690)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (2018) (1690)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. (2015) (1280)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. (2019) (1165)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. (2016) (768)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (626)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. (2018) (595)
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. (2016) (575)
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy (2018) (529)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer (2018) (508)
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC (2015) (473)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. (2017) (438)
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas (2011) (368)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (355)
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer (2011) (343)
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. (2016) (297)
Are G3 ENETS neuroendocrine neoplasms heterogeneous? (2013) (286)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. (2019) (285)
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019) (275)
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. (2013) (270)
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients (2017) (268)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. (2015) (262)
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. (2016) (234)
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. (2018) (232)
Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. (2020) (232)
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (231)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. (2015) (222)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. (2019) (194)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. (2021) (158)
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA (2017) (152)
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer (2022) (150)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS (2019) (146)
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. (2019) (143)
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. (2019) (141)
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). (2014) (139)
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (138)
Lung cancer in never-smokers (2015) (138)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (133)
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. (2016) (128)
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. (2013) (128)
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial (2015) (121)
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer (2020) (119)
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. (2015) (114)
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities (2017) (112)
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments (2016) (111)
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer (2015) (109)
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers (2016) (108)
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial. (2020) (105)
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies (2016) (103)
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. (2017) (102)
MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer (2010) (97)
GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. (2015) (96)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. (2020) (94)
Uncertain benefit from surgery in patients with lung metastases from breast carcinoma (2004) (93)
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. (2018) (92)
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) (91)
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors (2019) (87)
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line (2017) (86)
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer (2019) (84)
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. (2020) (80)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. (2017) (78)
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer (2019) (70)
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups (2017) (68)
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. (2021) (65)
Differential expression of biomarkers in men and women. (2009) (64)
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. (2019) (62)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. (2019) (62)
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. (2020) (59)
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis (2019) (59)
Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. (2011) (58)
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial (2017) (57)
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer (2019) (54)
Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy (2020) (51)
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. (2010) (51)
Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. (2017) (50)
1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial (2020) (50)
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). (2015) (49)
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience (2016) (46)
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer (2016) (45)
Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. (2017) (44)
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17 (2020) (44)
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation. (2018) (42)
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. (2020) (40)
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? (2014) (40)
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. (2012) (38)
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. (2020) (37)
Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression. (2019) (35)
Bevacizumab in non-small-cell lung cancer: a review (2011) (35)
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations (2021) (35)
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. (2017) (35)
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. (2019) (34)
OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01 (2021) (33)
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. (2021) (33)
Identification of driver mutations in lung cancer: first step in personalized cancer (2013) (32)
Small cell lung cancer: a slightly less orphan disease after immunotherapy. (2021) (32)
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer (2019) (32)
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. (2020) (32)
LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial (2020) (31)
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. (2012) (31)
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. (2019) (30)
Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis. (2021) (30)
Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies (2019) (30)
P1.07-012 Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort: Topic: Drug Treatment Alone and in Combination with Radiotherapy (2017) (27)
LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) (2014) (27)
Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer (2018) (26)
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. (2010) (26)
ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. (2022) (26)
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study (2021) (25)
MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). (2013) (25)
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. (2021) (25)
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) (2020) (25)
Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma (2012) (25)
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. (2019) (25)
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer (2020) (25)
1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO) (2017) (25)
Durvalumab for the treatment of non-small cell lung cancer (2018) (24)
Safety of osimertinib in EGFR-mutated non-small cell lung cancer (2018) (24)
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment. (2018) (24)
Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. (2016) (23)
An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). (2016) (23)
Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers (2008) (23)
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer (2019) (22)
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. (2015) (22)
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer (2015) (22)
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. (2009) (22)
p38 mitogen‐activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients (2012) (21)
Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. (2018) (21)
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. (2017) (21)
Three-year overall survival update from the PACIFIC trial. (2019) (21)
LBA3A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC – UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA (2015) (19)
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). (2019) (19)
Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. (2021) (19)
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases (2019) (19)
Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer. (2016) (19)
449PDUPDATED SAFETY AND EFFICACY FROM A PHASE I STUDY OF AZD9291 IN PATIENTS (PTS) WITH EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (18)
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience (2019) (18)
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression (2020) (18)
Three-year overall survival update from the PACIFIC trial (2019) (18)
Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC). (2020) (18)
Impact of COVID-19 on healthcare organisation and cancer outcomes (2021) (18)
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome (2020) (17)
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. (2021) (17)
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. (2016) (17)
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (17)
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy (2020) (16)
LBA58_PRSecond or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial (2017) (16)
Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM) (2016) (16)
LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial (2022) (16)
Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade (2021) (16)
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. (2019) (15)
Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated (2019) (15)
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. (2022) (15)
Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) (2019) (15)
Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation. (2009) (15)
Intervention in gastro-enteropancreatic neuroendocrine tumours. (2012) (15)
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy. (2012) (15)
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. (2022) (14)
Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response (2019) (14)
Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma. (2020) (14)
Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. (2018) (14)
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer (2014) (14)
128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes (2018) (14)
Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer. (2020) (14)
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. (2020) (14)
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer (2020) (13)
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial (2022) (13)
Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC) (2016) (13)
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study (2017) (13)
Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study (2017) (13)
Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. (2015) (13)
Durvalumab in non-small-cell lung cancer patients: current developments. (2018) (12)
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient (2015) (12)
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors (2021) (12)
Abstract 1015: P38 mitogen-activated protein kinase signaling and viability of lung cancer cells from never or light smoker patients (2011) (12)
Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment (2019) (12)
Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO). (2019) (12)
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. (2021) (12)
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report (2020) (11)
OA07.01 Osimertinib Plus Platinum/Pemetrexed in Newly-Diagnosed Advanced EGFRm-Positive NSCLC; The Phase 3 FLAURA2 Study (2019) (11)
MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma (2018) (11)
Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial. (2020) (11)
Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies. (2016) (11)
Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients. (2018) (11)
The role of brigatinib in crizotinib-resistant non-small cell lung cancer (2018) (11)
Phase I and pharmacokinetic study of vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results (2005) (11)
How Far We Have Come Targeting BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC) (2021) (11)
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay (2020) (11)
Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC). (2016) (10)
1323PBaseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (2017) (10)
Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases. (2020) (10)
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice? (2015) (10)
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer (2020) (10)
[Sleep apnea syndrome in the elderly]. (2003) (10)
P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (2017) (10)
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients (2017) (9)
Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO). (2018) (9)
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. (2017) (9)
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. (2016) (9)
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma (2020) (8)
Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology (2017) (8)
Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. (2018) (8)
Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (2019) (8)
Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients (2019) (8)
1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts) (2020) (8)
Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer (2016) (8)
1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study (2020) (8)
ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report. (2012) (8)
P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients (2018) (8)
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution. (2014) (7)
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. (2021) (7)
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer (2021) (7)
Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome. (2020) (7)
BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. (2018) (7)
MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO) (2017) (7)
Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). (2022) (7)
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer (2021) (6)
3025 Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT) (2015) (6)
MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study (2017) (6)
1270PLEVELS OF EGFR T790M IN PLASMA DNA AS A PREDICTIVE BIOMARKER FOR RESPONSE TO AZD9291, A MUTANT-SELECTIVE EGFR KINASE INHIBITOR. (2014) (6)
MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC (2019) (6)
MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy (2019) (6)
O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response (2019) (6)
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. (2021) (6)
P1.04-001 Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results (2017) (6)
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes (2021) (6)
Autoimmune protein S activity deficiency following a Q fever (2007) (6)
Have We Really MET a New Target? (2018) (6)
MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01 (2021) (6)
Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) (2017) (6)
P1.01-41 A Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer (2018) (5)
A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer. (2019) (5)
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)]. (2011) (5)
[DNA repair pathways and non-small cell lung cancer: clinical perspectives]. (2011) (5)
OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study (2018) (5)
Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors (2017) (5)
[Second generation ALK inhibitors in non-small cell lung cancer: systemic review]. (2015) (5)
Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial). (2018) (5)
Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. (2020) (5)
1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5). (2014) (5)
Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial (2017) (5)
Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC. (2018) (5)
Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib? (2016) (5)
Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials (2013) (5)
Are we reproducible in measurement of NET liver metastasis? (2017) (4)
P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy (2018) (4)
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update (2021) (4)
Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2023) (4)
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy (2020) (4)
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC. (2019) (4)
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]. (2007) (4)
3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (2019) (4)
Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients. (2016) (4)
Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC (2019) (4)
Safety of bevacizumab in cancer patients with inflammatory bowel disease. (2019) (4)
[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance]. (2015) (4)
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (2023) (4)
Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. (2022) (4)
Brigatinib in pretreated patients with ALK-positive advanced NSCLC. (2019) (4)
Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. (2017) (4)
1164PPatterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression (2017) (4)
Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases. (2019) (4)
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer (2020) (4)
LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC (2017) (4)
1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5). (2014) (4)
Feasibility of a video-based cognitive behavioral therapy for insomnia in French adult cancer outpatients: results from the Sleep-4-All-1 study (2021) (4)
MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer. (2009) (4)
112PPathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC) (2017) (4)
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. (2020) (4)
MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer (2019) (4)
464PPRELIMINARY AZD9291 WESTERN AND ASIAN CLINICAL PHARMACOKINETICS (PK) IN PATIENTS (PTS) AND HEALTHY VOLUNTEERS (HV): IMPLICATIONS FOR FORMULATION, DOSE AND DOSING FREQUENCY IN PIVOTAL CLINICAL STUDIES. (2014) (3)
Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC) (2021) (3)
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report (2021) (3)
Towards personalized lung cancer CT screening in Europe (2020) (3)
100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial (2021) (3)
Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients. (2022) (3)
Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial". (2016) (3)
[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]. (2009) (3)
Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC). (2009) (3)
18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data (2020) (3)
Analysis of single circulating tumor cells (CTCs) to identify resistance mutations to ALK-inhibitors in both ALK-gene and bypass oncogenic pathways. (2018) (3)
Small cell lung cancer and other thoracic malignancies (2012) (3)
Abstract 4581: Feasibility of an amplicon-based liquid biopsy forALKandROS1fusions in advanced non-small cell lung cancer (NSCLC) patients (2018) (3)
Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib (2021) (3)
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. (2022) (3)
1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations (2021) (3)
AZD3759 for CNS metastases in EGFR-mutant lung cancer. (2017) (3)
Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study. (2021) (3)
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study (2022) (3)
1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib (2021) (3)
Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer. (2020) (3)
MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC (2019) (3)
[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. (2011) (3)
MA21.09 Tyrosine Kinase Inhibitors' Plasma Concentration and Oncogene-Addicted Advanced Non-Small Lung Cancer (aNSCLC) Resistance (2019) (3)
ASSOCIATION OF LIPI SCORE WITH IMMUNOTHERAPY OUTCOMES IN ELDERLY POPULATION (2019) (3)
P3.02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients: Topic: IT Biomarkers (2017) (3)
Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants (2022) (3)
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. (2022) (3)
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. (2017) (3)
Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063 (2017) (3)
Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). (2019) (3)
P3.02b-102 Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients: Topic: EGFR RES (2017) (2)
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. (2022) (2)
LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC) (2021) (2)
Safety of current immune checkpoint inhibitors in non-small cell lung cancer (2021) (2)
1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study) (2020) (2)
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease (2022) (2)
[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments]. (2011) (2)
Late-Breaking Abstracts e 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (2014) (2)
Abstract 3192: Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples (2016) (2)
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients. (2018) (2)
ACUTE TUBULAR NECROSIS DUE TO RHABDOMYOLYSIS RESULTING FROM INFLUENZA A INFECTION (2006) (2)
PV-0208 Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT (2019) (2)
[Simultaneous occlusion of the abdominal aorta and both internal carotid arteries as the presenting symptoms of left atrial myxoma]. (2001) (2)
FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront. (2021) (2)
Fully Integrated Quantitative Multiparametric Analysis of Non–Small Cell Lung Cancer at 3-T PET/MRI (2021) (2)
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer. (2021) (2)
Reply to N. Singh et al. (2016) (2)
A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer. (2015) (2)
Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. (2017) (2)
Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model. (2018) (2)
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts). (2019) (2)
FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study (2021) (2)
1327PThe Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients (2017) (2)
Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts). (2019) (2)
P1.01-89 A Multicenter Phase 1/2a Trial of CLN-081 in NSCLC with EGFR Exon 20 Insertion Mutations (2019) (2)
975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial (2022) (2)
Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001). (2019) (2)
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]. (2010) (2)
Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI). (2018) (2)
Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. (2018) (2)
Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study (2019) (2)
Focus on Recommendations for the Management of Non-small Cell Lung Cancer (2019) (2)
Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study (2016) (2)
P1.13-09 Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study) (2018) (2)
Abstract 2597: Development and characterization of novel non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs)-derived xenograft (CDX) models (2018) (2)
Biosimilars in an era of rising oncology treatment options. (2021) (2)
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. (2022) (2)
Cannabis use and lung cancer: time to stop overlooking the problem? (2021) (2)
Tumor Treating Fields plus chemotherapy for first-line treatment of malignant pleural mesothelioma: Final Results of the STELLAR Trial (2019) (2)
Osimertinib in EGFR T790M positive advanced NSCLC (aNSCLC) – real–life data from the French temporary authorization for use (ATU) program (2016) (2)
Reply to the letter to the editor 'What is the clinical impact of the LUX-Lung 5 trial?' by Addeo. (2016) (2)
Abstract 2250: STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance (2016) (2)
1387P Phase Ib study of LXH254 + LTT462 in patients with KRAS- or BRAF-mutant NSCLC (2020) (2)
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry (2022) (1)
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience (2021) (1)
Abstract B45: Upfront genomic testing in non-small cell lung cancer (NSCLC) patients: Preliminary result of the MSN study (2012) (1)
1386OCancer cachexia (CAX), anorexia and muscle wasting (sarcopenia) assessment in non-small cell lung cancer (NSCLC): an observational study in 531 patients (2017) (1)
[Role of immunotherapy in locally advanced non-small cell lung cancer]. (2020) (1)
STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma. (2019) (1)
MA 05.03 The Early Monitoring of Derived Neutrophil-To Lymphocyte Ratio (dNLR) Could Be a Surrogate Marker of Benefit of Immunotherapy in NSCLC (2017) (1)
185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03) (2021) (1)
MA25.03 Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients (2019) (1)
P-566 Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Phase I and pharmacokinetic study (2005) (1)
3081 Molecular Tumor Board (MTB) in non-small cell lung cancers (NSCLC) to optimize targeted therapies: 4 years' experience at Gustave Roussy (2015) (1)
Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report (2022) (1)
RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. (2023) (1)
976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01 (2022) (1)
158P Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry (2022) (1)
MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma (2019) (1)
184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer (2021) (1)
Association of metastatic pattern and molecular status in metastatic lung non-small cell lung cancer adenocarcinomas (2019) (1)
Ongoing progress in BRAF-mutated non-small cell lung cancer. (2022) (1)
104PDPHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC) (2015) (1)
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score (2022) (1)
1377P Exploratory analyses of efficacy from a phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC (2020) (1)
MA11.02 Mutational Burden in Pulmonary Neuroendocrine Tumors (puNETs) (2017) (1)
34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions (2022) (1)
[Pneumoperitoneum and pneumomediastinum complicating non-invasive ventilation]. (2005) (1)
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer (2019) (1)
P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients (2018) (1)
P1.05 Upfront Genomic Testing for Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Regimen: Preliminary Result of the Msn Study (2012) (1)
HLA-A2 and immune checkpoints inhibitors in advanced non-small cell lung cancer (NSCLC) patients (2016) (1)
P3.02c-032 Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients: Topic: IT (2017) (1)
Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). (2017) (1)
KRAS in NSCLC: State of the Art and Future Perspectives (2022) (1)
P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients (2018) (1)
Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer (2021) (1)
1331TiPPHASE I STUDY OF TREMELIMUMAB (TREM) IN COMBINATION WITH GEFITINIB (GEF) IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (EGFR-MUT) NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (1)
Abstract 1867: Characterization of multiple driver alterations in acquired resistance to osimertinib inEGFR-mutated lung cancer: implementation of single cell approaches (2020) (1)
Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC. (2018) (1)
ERCC1 as Relevant Targets in the DNA Repair Pathway (2007) (1)
[Managing nutritional support in thoracic oncology]. (2013) (1)
MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer (2018) (1)
P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients (2018) (1)
O10.4AZD9291 a novel EGFR-TKI that overcomes T790M-mediated resistance in NSCLC (2015) (1)
1787P RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC (2021) (1)
1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC (2021) (1)
3076 Tumor control of advanced pulmonary carcinoid tumors with somatostatin analogs: Experience at Gustave Roussy (2015) (1)
Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report (2022) (1)
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib (2022) (1)
1381TiPA randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial (2017) (1)
Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC) (2019) (1)
1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC) (2021) (1)
MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer. (2009) (1)
MA26.10 CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC (2018) (1)
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma (2023) (1)
Abstract 1715: High ALK gene copy number as a predictor of response to crizotinib in non-small cell lung cancer cell lines (2012) (1)
Acute tubular necrosis tubular necrosis due to rhabdomyolysis resulting from influenza infection (2006) (1)
Abstract A51: Phase I, safety, tolerability and preliminary efficacy study of Tremelimumab (Trem) in combination with Gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM) (2015) (1)
3000 Chemo-radiation (CRT) and mutation profile in stage III Non Small Cell Lung Cancer (NSCLC): An analysis of the prognostic value (2015) (0)
1070P Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC) (2022) (0)
Efficacy and Toxicity Observed in Malignant Pleural Mesothelioma Patients Treated in Phase I Trials at a Single Institution (2012) (0)
378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma (2021) (0)
PO-1255 Retrospective analysis of synchronous NSCLC stage IV oligometastatic treated with local treatments (2022) (0)
Abstract 1217: Chromosomal imbalances detected by microarray CGH in malignant pleural mesothelioma. (2013) (0)
P34.06 The Clinical Utility of Liquid Biopsy by Digital Droplet PCR in Patients with Advanced NSCLC (2021) (0)
Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report (2022) (0)
Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer (2022) (0)
PO-1246 Lung SBRT after pneumonectomy (2022) (0)
75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC) (2023) (0)
Targeting ALK-rearranged non-small-cell lung cancer: an update. (2017) (0)
P14.03 Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy (2021) (0)
1282P Biology of immune resistance in oncogenic driven advanced non-small cell lung cancer (aNSCLC) (2021) (0)
Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression. (2019) (0)
P1.16-02 Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale (2022) (0)
Abstract 1470: Detection of circulating tumor cells harboring a uniqueALKrearrangement inALK-positive non-small cell lung cancer. (2013) (0)
STELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma. (2018) (0)
[Angiogenesis targeting in lung cancers]. (2007) (0)
Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay. (2018) (0)
Outcomes of extended resection for locally advanced thymic malignancies. (2023) (0)
Novel mutations in sporadic typical carcinoids of the lung (lung-TC): Tumor genomic profile by next generation sequencing (NGS). (2016) (0)
Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial. (2017) (0)
P84.01 The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients. (2021) (0)
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer (2022) (0)
Abstract CT141: Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial) (2018) (0)
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression (2020) (0)
P2.07-060 Response Assessment and Subgroups Analysis According to the Lung Immune Prognostic Index (LIPI) for Immunotherapy in Advanced NSCLC Patients (2017) (0)
Liquid biopsies could be superior to tumor biopsy to provide a molecular profile in non-small cell lung cancer (NSCLC) patients (2016) (0)
Performant gene expression signatures predicting overall survival in resected stage I NSCLC have potential for translation in the clinic (2014) (0)
9055 Outcome of non-small-cell lung cancer (NSCLC) patients treated for brain metastases (BM) in a single institution (2009) (0)
284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC) (2021) (0)
A Patient-Centered Model of Fast-Track Lung Cancer Diagnosis. (2023) (0)
Deciphering the metabolism/vascularization regional interlinks in primary NSCLC First-in human simultaneous full kinetic 18F-FDG PET-MRI voxel-wise analysis (2020) (0)
4P FDG PET derived metabolic tumor volume (MTV) and its transcriptomic correlates as biomarker to predict efficacy of immune checkpoint inhibitors (ICB) alone or in combination with chemotherapy in advanced NSCLC: A multicentric study (2022) (0)
F-FDG PET and DCE kinetic modeling and their interlinks in primary NSCLC: First-in human simultaneous [18F]FDG PET-MRI voxel-wise correlation analysis Running title: dynamic [18F]FDG PET/DCE-MRI interlinks in NSCLC (2020) (0)
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]. (2014) (0)
121P RAS precision medicine trans-atlantic partnership: Multicentre analysis of RAS and NF1 co-mutations in advanced NSCLC (2021) (0)
P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25% (2018) (0)
Efficacy of dabrafenib-trametinib combination in BRAF V600E-mutated metastatic non–small cell lung cancer: Results of the IFCT-2004 BLaDE cohort. (2022) (0)
P2.06-005 Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC: Topic: Phase I Trials (2017) (0)
Gemcitabine, Ifosfamide, and Cisplatin Combination (GIP) in Treatment of Patients With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer: Results of a Phase II Study (2006) (0)
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. (2022) (0)
1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer (2021) (0)
P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT Biomarkers (2017) (0)
9118 Effect of chemotherapy (CT) in patients (pts) with resected small-cell (SCLC) or large-cell neuro endocrine carcinoma (LCNEC) (2009) (0)
P1.10-06 Pathological Characterization of Radon-Induced Lung Cancer in Rats (2019) (0)
P1.04-31 Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (2019) (0)
Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma (2022) (0)
ES14.04 First Line for Rare Mutations (RET, BRAF, HER2) (2019) (0)
Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer (2019) (0)
P1.03-013 Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (2017) (0)
144PD Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors (2018) (0)
Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients. (2019) (0)
Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI). (2018) (0)
Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). (2018) (0)
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. (2022) (0)
Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts). (2019) (0)
Acquired resistance mechanisms to osimertinib: The constant battle. (2023) (0)
Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients. (2018) (0)
Abstract LB-072: Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017 (2016) (0)
Abstract 4019: RET-MAP: An international multi-center study of patients with advanced non-small cell lung cancer and RET fusions (2022) (0)
[Towards a histologically guided management for NSCLC]. (2009) (0)
18F-FDG PET and DCE kinetic modeling and their interlinks in primary NSCLC: First-in human simultaneous [18F]FDG PET-MRI voxel-wise correlation analysis (2020) (0)
Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study. (2018) (0)
MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (2018) (0)
1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma (2021) (0)
Oncogene addiction and immune escape: friends or foes? (2020) (0)
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer (2023) (0)
Abstract CT201: Final results of Phase II STELLAR trial: TTFields with chemotherapy in unresectable malignant pleural mesothelioma (2019) (0)
Abstract 3418: Alterations in PIK3CA/PTEN as resistance mechanisms in lung cancer patients progressing on first-line next generation EGFR/ALK tyrosine kinase inhibitors (2023) (0)
1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy (2021) (0)
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC (2022) (0)
Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity? (2019) (0)
The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer (2016) (0)
P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients (2021) (0)
Abstract 311: Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer (2019) (0)
Comparative use of perioperative chemotherapy (CT) in non-small cell lung cancer (NSCLC) between 2004 and 2007. (2009) (0)
ALK-amplified circulating tumor cells as a surrogate marker for crizotinib benefit in ALK-rearranged non-small cell lung cancer patients. (2016) (0)
162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumors (2021) (0)
9066 POSTER High ALK Gene Copy Number in Non-small Cell Advanced Lung Cancers (2011) (0)
P2.06-01 STELLAR Trial: Radiological Response Patterns of TTFields Plus Chemotherapy in First-Line Treatment of Malignant Pleural Mesothelioma (2019) (0)
18F-FDG PET–derived parameter total lesion glycolisis (TLG) as a tool to stratify patients (pts) with advanced non–small cell lung cancer (aNSCLC) treated with immunotherapy. (2022) (0)
Abstract 595: Patterns and dynamics of genome instability drive metastatic activity in non-small cell lung cancer (NSCLC) circulating tumor cell (CTC)-derived xenograft (CDX) models (2021) (0)
EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront (2022) (0)
25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) (2021) (0)
P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients (2018) (0)
169P Characteristics of clonal hematopoiesis (CH) in patients with non-small cell lung cancer (NSCLC): A retrospective analysis of plasma cell-free DNA (cfDNA) comprehensive genomic profiling (2022) (0)
38P Single molecule localization microscopy for extracellular vesicles detection in cancer (2022) (0)
1090P HER2 copy number variation in non-small cell lung cancer (NSCLC) (2022) (0)
P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases (2018) (0)
Genomic profile in pulmonary neuroendocrine tumors (puNETs): the whole-exome sequencing (WES) as a strategic tool (2016) (0)
Detection of Circulating Tumour Cells in Peripheral Blood of Patients With Malignant Pleural Mesothelioma (2012) (0)
Abstract 1034: Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions (2023) (0)
Abstract 856: Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib (2016) (0)
Abstract 3654: Identification of resistance mutations to crizotinib through circulating tumor cell (CTC) analysis inALK-rearranged non-small-cell lung cancer (NSCLC) (2018) (0)
MA 11.01 Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC) (2017) (0)
Differential epithelial and mesenchymal CTC profiling according to non-small cell lung cancer (NSCLC) molecular subtype. (2016) (0)
Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data. (2023) (0)
42P Pleural effusion is a negative prognostic factor for immunotherapy in non small cell lung cancer (NSCLC): The PLUIE study (2020) (0)
OA03.07 Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study (2021) (0)
EP14.01-020 Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Therapy in Treatment-Naïve Extensive Stage Small Cell Lung Cancer (2022) (0)
An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer (2022) (0)
Abstract 1951: Circulating tumor cell-derived explant models reveal DNA damage response-based therapeutic opportunities in non-small cell lung cancer (2022) (0)
P2.01-038 Determinants of Frailty and Treatment Toxicity in Non-Small Cell Lung Cancer Patient (2017) (0)
P2.03b-050 Prognostic Value of HLA-A2 Status in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: Biomarkers (2017) (0)
Weight, skeletal muscle mass, and adipose tissue loss during lung cancer patients' treatment. (2014) (0)
196O STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma (2019) (0)
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer (2019) (0)
366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study (2020) (0)
1735P Circulating T-cell immunosenescence in patients with thymic epithelial tumors (TETs) (2021) (0)
OA03.08 Clinical Utility of CTDNA Driver Genomic Alterations (GA) Directing Targeted Therapy in Untreated Advanced NSCLC Patients (2019) (0)
[Sleep apnea syndrome in the elderly]. (2004) (0)
PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer (2017) (0)
Epoetin beta treatment for anemia in lung cancer patients under chemotherapy: results of a large prospective cohort study: P1-252 (2007) (0)
EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study. (2021) (0)
Unexpected cardiotoxicity in HER2-mutant non-small cell lung cancer patients treated with trastuzumab deruxtecan (2022) (0)
107PDAFATINIB (A) PLUS PACLITAXEL (P) FOLLOWING PROGRESSION ON A MONOTHERAPY IN PATIENTS (PTS) WITH METASTATIC NON–SMALL-CELL LUNG CANCER (NSCLC) WHO PREVIOUSLY BENEFITED FROM ERLOTINIB (E)/GEFITINIB (G): A GLOBAL RANDOMISED PHASE III TRIAL–LUX-LUNG 5 (LL5) (2015) (0)
Molecular testing in older patients treated for an advanced or metastatic nonsquamous non-small-cell lung cancer (2021) (0)
[Towards customized therapy for non small cell lung cancer]. (2008) (0)
259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota (2022) (0)
22P Clinical utility of ddPCR for detection of sensitizing and resistance EGFRm in pts with advanced NSCLC (2021) (0)
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance (2022) (0)
Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC). (2019) (0)
P90.04 RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Pooled Analysis of RAS Pathway Mutations in Advanced NSCLC (2021) (0)
Abstract 598: Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling inBRAF-mutant non-small cell lung cancer (2021) (0)
OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology (2017) (0)
110P Prognostic and predictive value of lymphovascular invasion and lymph node status among breast cancer subtypes (2017) (0)
A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs) (2019) (0)
463 Vibostolimab plus pembrolizumab with/without docetaxel vs docetaxel in NSCLC after platinum chemotherapy and immunotherapy (2021) (0)
P3.02c-031 Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT (2017) (0)
1731P Lung cancer predisposition in Li-Fraumeni syndrome: Cohort from Gustave Roussy Institute (2022) (0)
403OPACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC (2017) (0)
CMAR_A_292730 2805..2810 (2021) (0)
Gene expression profiling robustly predicts the outcome of patients diagnosed with early stage lung adenocarcinoma (2014) (0)
P1.08-009 Neutrophilia as Prognostic Biomarker in Locally Advanced Stage III Lung Cancer (2017) (0)
1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02) (2021) (0)
1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma (2022) (0)
RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC). (2019) (0)
MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC (2021) (0)
1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC) (2021) (0)
Nuclear expression of CXCR4 is an independent prognostic factor for overall and progression-free survival in malignant pleural mesothelioma. (2004) (0)
[ERCC1 and lung cancer]. (2010) (0)
Small-cell lung cancer and large-cell neuroendocrine tumors of the lung (2013) (0)
Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. (2017) (0)
Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03 (2022) (0)
145P Everolimus for the treatment of thymic epithelial tumors (TETs): A real-world experience (2022) (0)
Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence. (2018) (0)
Abstract CT213: Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC) (2020) (0)
P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC (2021) (0)
941P PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial (2022) (0)
EP08.02-060 How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry (2022) (0)
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. (2023) (0)
1727P Factors associated with unplanned hospitalization among patients with lung cancer (2021) (0)
Abstract 2357: Gene expression profiling robustly predicts the outcome of patients diagnosed with early stage lung adenocarcinoma (2014) (0)
Abstract 2254: Variations in the epithelial-mesenchymal transition (EMT) program by non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) do not influence survival (2016) (0)
Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern: A free webtool powered by artificial intelligence. (2020) (0)
EP-1250: Outcome after stereotactic radiotherapy for brain metastasis of lung cancer: a retrospective study (2016) (0)
1618PDOverall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Planchard?

David Planchard is affiliated with the following schools:

Medical University of Vienna
Paris-Saclay University
Kansai Medical University
Kindai University
University of Western Australia